Please login to the form below

Not currently logged in
Email:
Password:

DMD

This page shows the latest DMD news and features for those working in and with pharma, biotech and healthcare.

Summit plunges after Duchenne disappointment

Summit plunges after Duchenne disappointment

Shares in UK biotech Summit Therapeutics plunged 80% after its treatment for Duchenne muscular dystrophy (DMD) failed in phase II trials. ... Nevertheless Glyn Edwards warned that cutbacks at the company would now be inevitable after losing its DMD

Latest news

  • Sarepta soars on positive Duchenne data Sarepta soars on positive Duchenne data

    Some studies have suggested that just 15% dystrophin expression is enough to prevent the contraction-induced muscle injury that characterises DMD. ... around 15% of DMD patients and has to be administered continually to exert its effects.

  • CHMP hands Santhera second ‘no’ in Duchenne muscular dystrophy CHMP hands Santhera second ‘no’ in Duchenne muscular dystrophy

    European regulatory advisers have refused to shift their negative position on Santhera’s Duchenne muscular dystrophy (DMD) drug Raxone (idebenone). ... reduces the risk of bronchopulmonary complications and hospitalisation in patients with DMD not

  • Transforming access in rare diseases Transforming access in rare diseases

    In Duchenne muscular dystrophy (DMD), for example, treatments from gene therapy to stem cell transplantation are all on the horizon, and all will need to be assessed by country healthcare systems ... In DMD, a standard outcome measure is the six-minute

  • Duchenne UK and pharma partner pilot data-sharing HTA approach Duchenne UK and pharma partner pilot data-sharing HTA approach

    A new initiative between medical charity Duchenne UK and several pharma companies will try to  increase the chances of patients with Duchenne muscular dystrophy (DMD) of accessing innovative treatments. ... The pharma partners - Roche, Sarepta

  • Sanofi launches French eHealth laboratory 39BIS Sanofi launches French eHealth laboratory 39BIS

    Dmd Santé, France eHealth Tech and Umanlife are among the laboratory’s initial external partners and its offering will include a six-month project process.

More from news
Approximately 7 fully matching, plus 28 partially matching documents found.

Latest Intelligence

  • Pharma deals during November 2014 Pharma deals during November 2014

    additional $160m more in near-term milestones if drisapersen, the late-stage drug for Duchenne muscular dystrophy (DMD), secures “ early” approval. ... Prosensa has been busy since drisapersen failed a pivotal phase III for DMD (failure to beat a

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Latest appointments

  • Catabasis hires Rick Modi as its chief business officer Catabasis hires Rick Modi as its chief business officer

    We look forward to leveraging his capabilities as we advance our clinical development pipeline, particularly CAT-1004 for Duchenne muscular dystrophy (DMD), and our lipid programmes, CAT-2003 and CAT-2054.”. ... we seek to bring disease-modifying

More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Quintiles Medical Communications

Quintiles’ award-winning medical communications group sits at the heart of the enterprise. We offer a range of innovative strategic services,...

Latest intelligence

Developing advocacy in the pharmaceutical industry.
The importance of advocacy programmes...
GDPR and events. What does the pharma industry need to know?
...
Digital trends in B2B sales - how far behind is Pharma?
The modern approach to B2B sales is data-driven, and enabled by digital tools....

Infographics